Abstract 1 -- PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
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Large‐scale genomic studies have demonstrated that approximately 50% of high‐grade serous ovarian cancers (HGSOCs) harbor genetic and epigenetic alterations in homologous recombination repair (HRR) pathway genes. The most commonly altered HRR genes are *BRCA1* and *BRCA2*, followed by other Fanconi anemia genes. Loss of HRR causes genomic instability, hyperdependence on alternative DNA repair mechanisms, and enhanced sensitivity to PARP‐inhibitors (PARPi) through the mechanism of synthetic lethality. PARP inhibitor resistance has emerged as a vexing clinical problem for the treatment of *BRCA1/2*‐deficient tumors. The most prevalent mechanism of PARPi resistance is secondary events that cancel the original HRR alteration and restore HRR proficiency. PARPi resistance also develops without restoration of HRR proficiency through enhanced replication fork stabilization. We recently made the surprising observation that *BRCA2*‐deficient tumor cells can stabilize their replication forks and become resistant to PARPi by downregulating the expression of various methyltransferases, such as MLL3/4 and EZH2. Reduced histone methylation limits the nucleolytic degradation of the forks. A molecular understanding of PARP inhibitor resistance mechanisms may allow the generation of a new class of drugs, or a repurposing of existing drugs, which may reverse this resistance and extend the use of PARP inhibitors to more tumor types.

Abstract 2 -- Assessing DNA Repairs in Clinical Trials
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Historically, tumors were classified as being radiation sensitive or radiation resistant based on organ of origin and histology. However, significant heterogeneity in response to radiation therapy can exist for any type of tumor, ranging from no response to pathologic complete response. Efforts have primarily focused on genotype of tumor, with *KRAS* and *KRAS/TP53* mutants being identified as remarkably radiation resistant. More recently, a radiation sensitivity index, based on expression of 10 hub genes identified by correlation with surviving fraction after 2 Gy (SF2), has been shown to predict radiation resistance in a number of clinical situations. Future efforts will involve further characterization of expression pre- and post-radiation to better identify potential future personalization opportunities with radiotherapy.

Abstract 3 -- Roles of Inhibition of ATR/ATM in Cancer Therapy
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PARP inhibitors (PARPi) selectively kill *BRCA1/2*‐deficient cells, but their efficacy in *BRCA*‐deficient patients is limited by drug resistance. We used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of *BRCA1* in homologous recombination and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of *BRCA1*, PARPi‐resistant cells regain RAD51 loading to DNA double‐stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with *BRCA1*‐proficient cells, PARPi‐resistant *BRCA1*‐deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRi) disrupt *BRCA1*‐independent RAD51 loading to DSBs and stalled forks in PARPi‐resistant *BRCA1*‐deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRi also overcomes the bypass of *BRCA1/2* in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of *BRCA*‐deficient cancers.

Abstract 4 -- Developing Therapies for
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Although selective kinase inhibitors have changed the standard of care in cancers that are driven by oncogenic kinases, there are currently few treatment options for malignancies that lack a "targetable" oncogenic driver. *Ras*-driven cancers are particularly problematic: agents that target individual Ras effector pathways are largely ineffective, and successful therapeutic combinations have not yet been identified; therefore, it is imperative that we rationally conceptualize and test new therapeutic combinations that (a) function to suppress orthogonal pathways in tumors, (b) converge on specific cancer cell vulnerabilities, and/or (c) exploit multiple therapeutic modalities. In this presentation, therapeutic strategies designed to co-target Ras effector kinases, epigenetic regulators, and/or immunoregulatory proteins will be discussed. By dissecting the mechanism by which promising combinations are working in preclinical models, we have uncovered nodal points of convergence between these distinct pathways and have identified new vulnerabilities that can be targeted in *Ras*-driven tumors.

Abstract 5 -- Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?
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*FGFR* gene aberrations are seen in 10%--20% of patients with intrahepatic cholangiocarcinoma (ICC), a rare and rapidly fatal malignancy of the intrahepatic bile ducts for which no targeted therapies are approved. The FGFR inhibitor BGJ398 displayed an encouraging overall response rate of 22% in a phase II trial in this population, but the durability of response was limited. We recently identified the first evidence of clinical acquired resistance to FGFR inhibition through serial plasma and biopsy analysis of patients with FGFR2 fusion‐positive ICC who were treated with BGJ398. This presentation will review the current landscape of FGFR inhibitors and FGFR resistance in cholangiocarcinoma.

Abstract 6 -- Intergenic Fusions as Frequent Drivers in Advanced HR+ Breast Cancer
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Most primary breast cancers express estrogen receptor and progesterone receptor and are responsive to therapies that target the estrogen response pathway. Nevertheless, a substantial minority of women treated for primary hormone receptor positive (HR+) disease exhibit hormonal therapy resistance, evidenced by the eventual development of metastatic disease. The pathways that confer hormonal therapy resistance have been studied extensively, yet our understanding of them remains relatively limited. We sought to uncover novel genetic drivers of HR+ breast cancer, using a targeted next‐generation sequencing approach for detecting expressed gene rearrangements without prior knowledge of the fusion partners. We identified intergenic fusions involving driver genes, including *PIK3CA, AKT3, RAF1,* and *ESR1*, in 14% (24 of 173) of unselected patients with advanced HR+ breast cancer. Fluorescence in situ hybridization analysis confirmed the corresponding chromosomal rearrangements in both primary and metastatic tumors. Expression of multiple novel kinase fusions in nontransformed cells activates phosphoprotein signaling and dramatically deregulates cell proliferation and survival in three‐dimensional culture, while expression in models of HR+ breast cancer modulates estrogen‐dependent growth and transcription and confers resistance to hormonal therapy in vitro and in vivo. Strikingly, decreased time‐to‐recurrence and shorter overall survival were observed in patients with rearrangement‐positive versus rearrangement‐negative tumors. Correspondingly, fusions were uncommon (\<5%) among a cohort of 300 patients with nonmetastatic HR+ breast cancer. Collectively, our findings identify expressed gene fusions as frequent and potentially actionable drivers in HR+ breast cancer.

Abstract 7 -- Genomic and Functional Characterization of Patient‐Derived Xenograft Models of Small Cell Lung Cancer
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Small cell lung cancer (SCLC) remains one of the most aggressive subtypes of lung cancer, and treatment strategies for this disease have remained virtually unchanged for more than 30 years. We have developed a platform for studying SCLC by generating patient‐derived xenograft models from both biopsy specimens and circulating tumor cells. We have characterized the genomic features of these models by whole exome sequencing to show that they faithfully recapitulate the genomics of the patient tumor, and further transcriptional and proteomic characterization is under way. Furthermore, we have developed models from patients at serial time points over the course of their treatments in our clinic, and we show drug sensitivities in the models accurately recapitulate the patient experience. We therefore argue that this platform will be a powerful tool for comparative therapeutic studies and biomarker development in SCLC.

Abstract 8 -- Antibody Drug Conjugates for Triple‐Negative Breast Cancer: Targeting Positive in the Negative
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Triple‐negative breast cancer (TNBC) refers to tumors that lack expression of estrogen receptor, progesterone receptor, and HER2; patients with metastatic TNBC have an aggressive disease. There is no targeted therapy approved for TNBC, and chemotherapy is the mainstay of management, but the duration of response with standard chemotherapy is usually short, with a median progression‐free survival of approximately 3 or 4 months, highlighting the need for better therapies. Antibody drug conjugates are comprised of antibodies linked to chemotherapy targeted for selective delivery to cancer cells, and the efficacy/toxicity ratio depends on careful selection of antigen, linker, and toxic payload. In this presentation, the clinical development of novel antibody drug conjugates in triple‐negative breast cancer will be reviewed, particularly anti‐Trop‐2 sacituzumab govitecan and the gp‐NMB‐specific glembatumumab vedotin, both of which are in advanced clinical stages of development, as well as potential combination strategies based on tumor biology and therapeutic resistance in triple‐negative breast cancer.

Abstract 9 -- PARP Inhibitors in Breast Cancer: Current Status and Future Directions
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Poly (ADP-ribose) polymerase (PARP) is a key enzyme in single-strand DNA break repair. PARP inhibition represents an attractive therapeutic strategy in oncology. This lecture will review development of PARP inhibitors in breast cancer, highlighting some of the challenges that have occurred along the way and focusing on the current and future directions. PARP inhibitors function by at least two important mechanisms to induce tumor cell death: (a) inhibition of PARP catalytic activity, preventing single-strand break repair leading to double strand breaks, and (b) PARP trapping on damaged DNA, which prevents the release of the PARP repair complex from damaged DNA. PARP inhibitors are currently approved for advanced ovarian cancer, and clinical activity has been demonstrated in prostate and breast cancer. In breast cancer, PARP inhibitor monotherapy activity has been clearly demonstrated in *BRCA1/2* mutation-associated breast cancer, with recent phase III data validating its activity compared with standard chemotherapy in advanced disease. Beyond *BRCA1/2*, additional breast cancer patient populations that may benefit from PARP inhibitor therapy, as well as biomarkers to predict response, remain unidentified. Triple-negative breast cancer with normal germline *BRCA1/2*, for example, has so far shown no significant response to PARP inhibition. Ongoing studies are evaluating the activity of PARP inhibitors in the adjuvant, neoadjuvant, and advanced settings. Combination therapies with chemotherapy, targeted therapy, and checkpoint inhibitor immunotherapy are under active investigation and will be reviewed.

Abstract 10 -- Ex Vivo Profiling of Immune Checkpoint Blockade: Developing a Functional Precision Medicine Platform for Immuno‐Oncology
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A major barrier to the development of effective therapeutic combinations that overcome intrinsic resistance to PD‐1 immune checkpoint blockade has been the paucity of ex vivo models that recapitulate the tumor immune microenvironment and are suitable for drug testing. We recently developed a novel platform for short‐term culture of patient‐ or murine‐derived organotypic tumor spheroids (PDOTS/MDOTS) that retain autologous infiltrating immune cells and respond to treatment with anti‐PD‐1 antibodies. Here we report that MDOTS from well‐established syngeneic mouse models not only recapitulate intrinsic response and resistance to PD‐1 blockade but also facilitate the identification of synergistic drug combinations. For example, using MDOTS derived from partially sensitive syngeneic models, we identified a unique immunomodulatory effect of a novel compound that potently synergized with ex vivo PD‐1 blockade. Synergistic anti‐tumor activity was confirmed in vivo, including evidence of long-term durable response and development of immunologic memory. These findings not only identify a specific drug combination that enhances the efficacy of PD‐1 immune checkpoint blockade but also unveil the immense potential of ex vivo profiling in MDOTS to screen the vast array of potential immune‐oncology agents to identify the most effective therapeutic combinations.
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The treatment of *EGFR*‐mutant lung cancer has seen significant advances in recent years. In this session, we will discuss the role of third‐generation EGFR tyrosine kinase inhibitors (TKIs) in the treatment of *EGFR*‐mutant lung cancer, review the critical role of cancer heterogeneity in the development of resistance to third‐generation EGFR TKIs, and explore potential treatment strategies to prevent or delay the development of resistance in the future.

Abstract 12 -- Financial Toxicity of Cancer
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Research demonstrates that patients with cancer experience substantial financial burden related to the disease and its treatment, yet financial burden among cancer survivors remains understudied. Studies suggest that patients with cancer experience financial issues such as job loss, missed work, and trouble obtaining affordable health insurance. Notably, patients with cancer often experience increased health care needs for years after their initial diagnosis. In addition, the high out‐of‐pocket medical costs coupled with the loss of income can further compound the economic hardships endured by patients with cancer. Financial burden can negatively impact patients\' health outcomes, such as their quality of life, symptom burden, and even survival. Importantly, in the modern era of cancer therapeutics, with patients living longer and drug prices increasing exponentially, patients with cancer are particularly vulnerable to the adverse financial consequences of their care. Patients' financial burden may influence their decision to forego needed care or to not properly adhere to prescribed therapies in an effort to defray costs. As a result, this can jeopardize the health and outcomes of these patients. Thus, the financial burden experienced by patients with cancer is an important issue with the potential to affect their quality of life and care.
